Mustang Bio, INC 10-Q quarterly reports

Mustang Bio reports continued operating losses and cash burn, while facing potential delisting from Nasdaq due to low stock price, despite advancements in its CAR T and oncolytic virus pipeline.

Mustang Bio reported a net loss of $955,000 for the first quarter of 2026, with ongoing concerns about Nasdaq listing compliance and future funding needs.

Mustang Bio reported significantly reduced net losses and increased cash reserves for the nine months ended September 30, 2025, driven by cost-cutting measures and financing activities, despite ongoing going concern doubts and program changes.

Mustang Bio, a clinical-stage biopharmaceutical company, reported significantly reduced net losses and increased cash reserves for the first half of 2025, driven by strategic cost-cutting measures and recent capital raises, though substantial doubt about its going concern status persists.

Mustang Bio reports a net loss of $0.2 million for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern.

Mustang Bio's Q3 2024 report reveals a significant reduction in operating expenses and a net loss of $14.8 million for the nine-month period, while also highlighting substantial doubt about the company's ability to continue as a going concern.

Mustang Bio's Q2 2024 report reveals significant losses, a strategic pivot towards MB-106, and substantial doubt about the company's ability to continue as a going concern.

Mustang Bio's first quarter 2024 results reveal a significant net loss and substantial doubt about the company's ability to continue as a going concern, despite a strategic pivot and workforce reduction.